Journal article

Subjective cognitive decline and rates of incident Alzheimer's disease and non-Alzheimer's disease dementia

Rosalinde ER Slot, Sietske AM Sikkes, Johannes Berkhof, Henry Brodaty, Rachel Buckley, Enrica Cavedo, Efthimios Dardiotis, Francoise Guillo-Benarous, Harald Hampel, Nicole A Kochan, Simone Lista, Tobias Luck, Paul Maruff, Jose Luis Molinuevo, Johannes Kornhuber, Barry Reisberg, Steffi G Riedel-Heller, Shannon L Risacher, Susanne Roehr, Perminder S Sachdev Show all

Alzheimer's & Dementia | WILEY | Published : 2019

Grants

Awarded by JPND - EURO-SCD


Awarded by European Commission


Awarded by German Federal Ministry of Education and Research (BMBF): Kompetenznetz Demenzen


Awarded by Alzheimer's Association


Awarded by ESPA-EU program Excellence Grant (ARISTEIA)


Awarded by Ministry for Health and Social Solidarity (Greece)


Awarded by National Health and Medical Research Center, Australia


Awarded by "Investissement d'Avenir" program


Awarded by Ce travail a beneficie d'une aide de l'Etat "Investissements d'avenir"


Awarded by program "Investissements d'avenir"


Awarded by United States Department of Health and Human Services (DHHS)


Awarded by National Institute on Aging


Awarded by NIA


Awarded by Alzheimer's Disease Neuroimaging Initiative (National Institutes of Health)


Awarded by DOD ADNI (Department of Defense)


Funding Acknowledgements

This work was supported by the Alzheimer's Association and the International Society to Advance Alzheimer's Research and Treatment (ISTAART) Subjective Cognitive Decline Professional Interest Area (PIA). The authors are grateful to Keith Fargo and April Ross (ISTAART) for facilitating SCD PIA meetings.R. Slot and S. Verfaillie are supported by a research grant from Gieske-Strijbis Fonds. W.M. van der Flier holds the Pasman chair. F. Jessen and S. Sikkes is recipient of JPND - EURO-SCD (grant no: JPND_PS_FP-689-019). The Alzheimer Center Amsterdam is supported by Alzheimer Nederland and Stichting VUmc fonds. The authors thank the collaborators from the DESCRIPA study for their work in the collection of the data. The DESCRIPA study group members include the following individuals: Merce Boada, Fundacio ACE, Barcelona, Spain; Peter Paul de Deyn, Institute Born Bunge, ZNA Middelheim, University of Antwerp, Antwerp, Belgium; Roy Jones, The Research Institute for the Care of Older People, Bath, UK; Giovanni Frisoni, IRCCS San Giovanni di Dio Fatebenefratelli, Brescia, Italy, and University Hospital and University of Geneva, Geneva, Switzerland; Luiza Spiru, 'Carol Davila' University of Medicine and Pharmacy, Bucharest, Romania; Flavio Nobili, Clinical Neurophysiology Service, Department of Neurosciences, Ophthalmology and Genetics, University of Genova, Genova, Italy; Yvonne Freund-Levi, Department of Neurobiology, Caring Sciences and Society (NVS), Division of Clinical Geriatrics, Karolinska Institutet, and Department of Geriatric Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden; Hilkka Soininen, Institute of Clinical Medicine, Neurology, University of Eastern Finland and Neurocenter, Neurology, Kuopio University; Frans Verhey, Department of Psychiatry and Neuropsychology, Maastricht University, School for Mental Health and Neuroscience, Alzheimer Centre Limburg, Maastricht, The Netherlands; Asa K. Wallin, Lund University, Clinical Sciences Malmo, Clinical Memory Research Unit, Lund, Sweden; Jacques Touchon, Institute National de la Sante et de la Recherche Medicinale INSERM U 888, Montpellier, France; Marcel Olde Rikkert, Department of Geriatrics, Radboud University Medical Centre, Nijmegen, The Netherlands; Anne-Sophie Rigaud, Department of Geriatrics, Hopital Broca, Paris, France; Roger Bullock, Kingshill Research Centre, Swindon, UK; Magda Tsolaki, Aristotle University of Thessaloniki, Memory and Dementia Center, 3rd Department of Neurology, "G Papanicolaou" General Hospital, Thessaloniki, Greece; Bruno Vellas, Department of Internal Medicine and Clinical Gerontology, Toulouse University Hospital, Toulouse, France; Gordon Wilcock, Department of Care of Elderly, University of Bristol, Frenchay Hospital, Bristol, UK; Harald Hampel, Universite Pierre et Marie Curie-Paris 6, AP-HP, Hopital de la Salpetriere, Paris, France; Lutz Froelich, Department of Geriatric Psychiatry, Zentralinstitut fur Seelische Gesundheit, University of Heidelberg, Mannheim, Germany.The authors acknowledge the sharing of data by the INSIGHT-preAD study and thank the INSIGHT-preAD collaborators for their work. The INSIGHT-preAD study group includes Hovagim Bakardjian, Habib Benali, Hugo Bertin, Joel Bonheur, Laurie Boukadida, Nadia Boukerrou, Enrica Cavedo, Patrizia Chiesa, Olivier Colliot, Bruno Dubois, Marion Dubois, Stephane Epelbaum, Geoffroy Gagliardi, Remy Genthon, Marie-Odile Habert, Harald Hampel, Marion Houot, Aurelie Kas, Foudil Lamari, Marcel Levy, Simone Lista, Christiane Metzinger, FannyMochel, Francis Nyasse, Catherine Poisson, Marie-Claude Potier, Marie Revillon, Antonio Santos, Katia Santos Andrade, Marine Sole, Mohmed Surtee, Michel Thie-baud de Schotten, Andrea Vergallo, Nadjia Younsi. INSIGHT-preAD Scientific Committee Members: Dubois B, Hampel H, Bakardjian H, Benali H, Colliot O, Habert Marie-O, Lamari F, Mochel F, Potier MC, Thiebaut de Schotten M. S. Vos receives research support from ZonMw. The DESCRIPA study was supported by the European Commission within the 5th Framework Program, contract number QLK-6-CT-2002-02455. The German DCN study has been supported by a grant from the German Federal Ministry of Education and Research (BMBF): Kompetenznetz Demenzen (01GI0420).The HELIAD study has been supported by the following grants: IIRG-09-133014 from the Alzheimer's Association; 189 10276/8/9/2011 from the ESPA-EU program Excellence Grant (ARISTEIA), which is cofunded by the European Social Fund and Greek National resources, DY2b/oij.51657/14.4.2009 from the Ministry for Health and Social Solidarity (Greece).N.A. Kochan and the Sydney Memory and Ageing Study were supported by grants from the National Health and Medical Research Center, Australia (350833, 1053804).The INSIGHT-preAD study was promoted by INSERM in collaboration with ICM, IHU-A-ICM and Pfizer and has received support within the "Investissement d'Avenir" (ANR-10-AIHU-06) program. The study was promoted in collaboration with the "CHU de Bordeaux" (coordination CIC EC7), the promoter of Memento cohort, funded by the Foundation Plan-Alzheimer. The study was further supported by AVID/Lilly. H. Hampel is supported by the AXA Research Fund, the "Fondation partenariale Sorbonne Universite" and the "Fondation pour la Recherche sur Alzheimer", Paris, France. Ce travail a beneficie d'une aide de l'Etat "Investissements d'avenir" ANR-10-IAIHU-06. The research leading to these results has received funding from the program "Investissements d'avenir" ANR-10-IAIHU-06 (Agence Nationale de la Recherche-10-IA Agence Institut Hospitalo-Universitaire-6). This Manuscript benefited from the support of the Program "PHOENIX" led by the Sorbonne University Foundation and sponsored by la Fondation pour la Recherche sur Alzheimer. Dr. Barry Reisberg's work on the project was supported in part by United States Department of Health and Human Services (DHHS) grants AG08051 and AG03051 for the National Institute on Aging, of the US National Institutes of Health, and by the Hagedorn Fund, the Stringer Foundation, the Louis J. Kay and June E. Kay Foundation, donations from Mrs. Miriam Glanbach and Dr. Felix Glanbach, and by a Clinical Research Development Fund of the New York University School of Medicine. A. Saykin and the Indiana Memory and Aging Study (IMAS) were supported by grants from the National Institute on Aging (P30 AG010133, R01 AG019771); S. Risacher was additionally supported by NIA K01 AG049050. ADNI data and sharing were funded by the Alzheimer's Disease Neuroimaging Initiative (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through contributions from Alzheimer's Association, Alzheimer's Drug Discovery Foundation, Araclon Biotech, BioClinica, Inc., Biogen Idec Inc., Bristol-Myers Squibb Company, Eisai Inc., Elan Pharmaceuticals, Inc., Eli Lilly and Company, EuroImmun, F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc., Fujirebio, GE Healthcare, IXICO Ltd., Janssen Alzheimer Immunotherapy Research & Development, LLC, Johnson & Johnson Pharmaceutical Research & Development LLC, Medpace, Inc., Merck & Co., Inc., Meso Scale Diagnostics, LLC, NeuroRx Research, Neurotrack Technologies, Novartis Pharmaceuticals Corporation, Pfizer Inc., Piramal Imaging, Servier, Synarc Inc., and Takeda Pharmaceutical Company.